Projects per year
Fingerprint
Dive into the research topics where Anke Maes is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
ANI224: Subsidy for organisation ORC day 2018 - Oncology Research Center day 2018. (Brussels, 19 October 2018)
30/04/19 → 30/06/20
Project: Fundamental
Research output
-
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis
Van der Vreken, A., Oudaert, I., Ates, G., Faict, S., Vlummens, P., Satilmis, H., Fan, R., Maes, A., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 28 Mar 2023, In: Journal of pathology. 260, 2, p. 112-123 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile13 Citations (Scopus)73 Downloads (Pure) -
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism
Satilmis, H., Verheye, E., Vlummens, P., Oudaert, I., Vandewalle, N., Fan, R., Knight, J. M., De Beule, N., Ates, G., Massie, A., Moreaux, J., Maes, A., De Bruyne, E., Vanderkerken, K., Menu, E., Sloan, E. K. & De Veirman, K., Jan 2023, In: Journal of pathology. 259, 1, p. 69–80 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile13 Citations (Scopus)86 Downloads (Pure) -
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Fan, R., Satilmis, H., Vandewalle, N., Verheye, E., Vlummens, P., Maes, A., Muylaert, C., De Bruyne, E., Menu, E., Evans, H., Chantry, A., De Beule, N., Hose, D., Törngren, M., Eriksson, H., Vanderkerken, K., Maes, K., Breckpot, K. & De Veirman, K., 17 Jan 2023, In: Journal for ImmunoTherapy Of Cancer. 11, 1, 9 p., A8.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Citations (Scopus)46 Downloads (Pure) -
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert, C., Van Hemelrijck, L. A., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 18 Aug 2022, In: Frontiers in Oncology. 12, 24 p., 979569.Research output: Contribution to journal › Article › peer-review
Open AccessFile10 Citations (Scopus)60 Downloads (Pure) -
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
Verheye, E., Melgar, J. B., Deschoemaeker, S., Raes, G., Maes, A., De Bruyne, E., Menu, E., Vanderkerken, K., Laoui, D. & De Veirman, K., 14 Jan 2022, In: International Journal of Molecular Sciences. 23, 2, 904.Research output: Contribution to journal › Scientific review › peer-review
Open Access35 Citations (Scopus)
Prizes
-
ASH Abstract Achievement Award
Maes, Anke (Recipient), 2017
Prize: Prize (including medals and awards)
-
-
34th General Annual Meeting of the Belgian Hematology Society
Anke Maes (Participant)
1 Feb 2019Activity: Participating in or organising an event › Participation in conference
-
LSM - Wide-ranging approaches in multi-color flow cytometry
Anke Maes (Participant)
23 Jan 2018Activity: Participating in or organising an event › Participation in workshop, seminar
-
ORC day 2018
Anke Maes (Participant)
19 Oct 2018Activity: Participating in or organising an event › Participation in workshop, seminar
-
33rd General Annual Meeting BHS
Anke Maes (Participant) & Astrid Muyldermans (Participant)
2 Feb 2018Activity: Participating in or organising an event › Participation in conference